Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Anika Therapeutics, Inc. | a6613123ex99_1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): February
14, 2011
Anika
Therapeutics, Inc.
(Exact Name of Registrant as Specified
in Its Charter)
|
Massachusetts |
000-21326 |
04-3145961 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
32 Wiggins Avenue, Bedford, Massachusetts |
01730 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant's Telephone Number, Including Area Code: (781) 457-9000
N/A
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On February 14, 2011, Anika Therapeutics, Inc. issued a press release announcing the date of its fourth-quarter and year-end financial results conference call and providing a regulatory timing update. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release issued by Anika Therapeutics, Inc. on February 14, 2011 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANIKA THERAPEUTICS, INC. |
||
|
|
||
|
February 15, 2011 |
By: |
/s/ Kevin W. Quinlan |
|
|
Kevin W. Quinlan |
|
|
|
Chief Financial Officer |
|
Exhibit Index
|
Exhibit No. |
Description |
| 99.1 |
Press Release issued by Anika Therapeutics, Inc. on February 14, 2011 |